Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
HIV-1p Inhibitor
NIT is an HIV-1 protease (HIV-1p) inhibitor, exhibiting Ki values of 96 μM for wild-type HIV-1p and 91 μM for multidrug-resistant HIV-1p. This compound demonstrates significant potential for studying HIV protease activity and developing therapeutic strategies against HIV infection. Its application in research may further elucidate mechanisms of viral resistance and aid in the design of more effective antiretroviral agents. -
HIV Protease Inhibitor
HIV-IN-11 is a potent HIV protease inhibitor that disrupts the activity of HIV-1 protease through competitive inhibition, with a Ki of 0.049 nM. This compound effectively inhibits the replication of HIV(IIIb)-infected MT4 lymphocytes at concentrations of 25.0-50.0 nM. Demonstrating a longer half-life compared to indinavir sulfate in animal models, HIV-IN-11 represents a promising candidate for second-generation HIV treatment research. -
HIV-1 Inhibitor
Mvt-101 is a hexapeptide-based inhibitor targeting HIV-1 protease. This compound functions as a reduced-peptide-bond inhibitor, effectively blocking protease activity and thereby inhibiting the replication of the HIV virus. Mvt-101 is particularly relevant for research in virology and therapeutics aimed at tackling HIV infection. -
HIV Protease Inhibitor
DMP 323 is a potent, nonpeptide cyclic urea inhibitor of HIV protease, targeting both HIV-1 and HIV-2. It functions as a competitive inhibitor by blocking the cleavage of peptide substrates and the HIV-1 gag polyprotein, demonstrating robust antiviral activity. DMP 323 exhibits comparable efficacy to leading HIV protease inhibitors while remaining effective in human plasma or serum, indicating low affinity for plasma proteins. Additionally, it shows minimal inhibition of mammalian proteases at higher concentrations, underscoring its selectivity for HIV protease. -
HIV-1 Protease Inhibitor
HIV-1 protease-IN-9 is a potent inhibitor of HIV-1 protease, exhibiting a Ki value of 0.028 nM. This compound demonstrates significant antiviral activity, with an IC50 of 66.8 nM, making it a valuable tool for research in HIV treatment and drug development. Its efficacy highlights its potential application in studies aiming to inhibit HIV replication and investigate resistance mechanisms. -
HIV-1 Protease Inhibitor
L-687908 is a highly potent HIV-1 protease inhibitor with a competitive inhibition constant (CIC95) of 12 nM. This compound effectively disrupts the proteolytic processing of viral polyproteins, thereby inhibiting viral replication. Its key biological activity makes it a valuable tool for antiviral research and the development of therapeutic agents targeting HIV-1. -
HIV Protease Inhibitor
AQ148 is a selective HIV-1 protease inhibitor with a Ki value of 137 nM. It demonstrates significant inhibitory activity against aspartic proteases from HIV-1 (IC50 = 1.5 μM), HIV-2 (IC50 = 3.4 μM), and simian immunodeficiency virus (SIV) (IC50 = 5 μM). This compound is useful for research applications focused on HIV pathogenesis and the development of antiviral therapies. -
HIV Protease Inhibitor
20(21)-Dehydrolucidenic acid A is a triterpenoid derived from the fruiting body of Ganoderma sinense, primarily targeting HIV protease. This compound exhibits modest inhibitory activity against HIV-1 protease, making it a valuable tool in the study of HIV pathogenesis and in the development of antiviral strategies. Its unique structure offers potential insights into therapeutic applications for HIV treatment. -
HIV Protease Inhibitor
U-85548E is an HIV protease inhibitor that demonstrates nanomolar affinity for the HIV-1 aspartic protease. This compound has been developed through investigations into its structure-activity relationships, proving effective against both HIV-1 and HIV-2 proteases. Its binding interactions have been characterized using X-ray crystallography and molecular modeling, making it a valuable tool for research in HIV drug development and mechanistic studies of protease inhibition. -
HIV-1 Protease Inhibitor
JE-2178 is an orally bioavailable inhibitor of HIV-1 protease, exhibiting potent antiviral activity. With an IC50 value of 15 nM and a Ki value of 0.318 nM, JE-2178 effectively targets the protease enzyme critical for viral replication. This compound is valuable for research applications focused on HIV-1 inhibition and the development of antiretroviral therapies. -
HIV-1 Protease Inhibitor
HIV-1 protease-IN-7 is a selective inhibitor of the HIV-1 protease, exhibiting an IC50 of 3.52 nM and an EC50 of 37 nM. This compound demonstrates potent antiviral activity, making it a valuable tool in the study of HIV-1 replication and protease function. Its efficacy positions it as a useful reagent for research applications aimed at developing antiviral therapies against HIV-1. -
HIV Protease Inhibitor
Kynostatin 272 is a potent inhibitor of the HIV protease, targeting the enzyme's active site by mimicking the substrate transition state. This mechanism effectively disrupts a critical stage in the replication cycle of the HIV virus. Kynostatin 272 serves as a valuable tool in HIV research, aiding in the development of therapeutic strategies for managing HIV and AIDS. -
HIV Protease Inhibitor
Stercobilin hydrochloride (mixture of isomers) serves as an HIV protease inhibitor, exhibiting a Ki value of 4 μM. This bile pigment, derived from gut bacteria metabolism, can promote pro-inflammatory responses in mouse macrophage RAW264 cells, including the upregulation of cytokines such as TNF-α and IL-1β. Applications of Stercobilin hydrochloride extend to the investigation of inflammatory processes and viral infections. -
HIV Protease Inhibitor
GS-9770 is an orally active inhibitor specifically targeting HIV protease, with a Ki of 0.16 nM. It demonstrates potent antiviral activity against both HIV-1 and HIV-2 strains, showing EC50 values ranging from 1.9 to 26 nM. In addition to its efficacy, GS-9770 is metabolically stable in human liver microsomes and exhibits favorable pharmacokinetic properties in Sprague Dawley rats, making it a valuable tool for research in HIV treatment. -
HIV Protease Inhibitor
L 756423 is a potent inhibitor of HIV protease, targeting the enzyme crucial for the maturation of infectious HIV particles. This compound exhibits significant antiviral activity, making it a valuable tool for research into HIV infection and the development of therapeutic strategies. Its effective inhibition of protease could contribute to understanding HIV lifecycle and resistance mechanisms. -
HIV Protease Inhibitor
R-87366 is a water-soluble inhibitor of HIV protease, demonstrating potent inhibition with a Ki value of 11 nM. This compound is instrumental in the study of human immunodeficiency virus (HIV) mechanisms and provides valuable insights for the development of antiviral therapies. R-87366 serves as a key reagent for research focused on combating HIV infections. -
HIV Protease Inhibitor
Lopinavir Metabolite M-1 is a potent HIV protease inhibitor with a Ki of 0.7 pM. This active metabolite exhibits significant antiviral activity in vitro, making it valuable for research on HIV treatment and drug resistance mechanisms. Its efficacy in inhibiting HIV replication underlines its relevance in antiviral studies and therapeutic development. -
HIV-1 Protease Inhibitor
HIV-1 protease-IN-2 is a highly potent inhibitor of HIV-1 protease, exhibiting an IC50 of 2.53 nM. This compound demonstrates significant antiviral activity against both DRV-sensitive and DRV-resistant strains of HIV-1. It is a valuable tool for researching antiretroviral therapies and understanding HIV resistance mechanisms. -
HIV-1 Protease Inhibitor
8-Prenylluteone is an HIV-1 protease inhibitor that demonstrates significant antiviral activity with an IC50 value of 4 μM. This compound is utilized in research focused on HIV-1 replication and its inhibition, making it a valuable tool for studying the effects of protease inhibition on viral pathogenesis and potential therapeutic strategies. -
HIV Protease Inhibitor
HIV protease-IN-1 is a potent non-peptidic inhibitor of HIV protease, designed to interfere with the viral life cycle. Its primary mechanism involves the inhibition of HIV protease, which is essential for the processing of viral polyproteins into functional proteins. This compound holds significant potential for research applications in the development of therapeutic strategies against AIDS and HIV-related pathologies. -
Renin/HIV-1 Protease Inhibitor
PD 134922 is a potent inhibitor of renin and HIV-1 protease, exhibiting an IC50 of 15 nM against HIV-1 protease. This compound is valuable in studies focused on the modulation of blood pressure regulation through renin inhibition and provides insights into HIV-1 protease activity. Its application extends to research in antiviral therapies and blood pressure-related disorders, making it a useful tool for scientists in pharmacological studies. -
HIV-1 Protease Inhibitor
HIV-1 protease-IN-12 is a potent inhibitor of HIV-1 protease, exhibiting an IC50 of 0.51 nM. This compound effectively targets both wild-type and drug-resistant variants of the enzyme, making it a valuable tool in HIV research. Its primary applications include the study of HIV-1 protease function and the development of antiviral therapies. -
HIV-1 PR/RT Inhibitor
HIV-1 inhibitor-53 is a dual inhibitor targeting HIV-1 protease (PR) and reverse transcriptase (RT). It demonstrates potent inhibitory activity with IC50 values of 1.93 nM for PR and 2.35 μM for RT, making it an important tool for studying HIV replication. This compound is suitable for research applications related to acquired immune deficiency syndrome (AIDS) and the development of antiretroviral therapies. -
HIV-1 Protease Inhibitor
HIV-1 protease-IN-8 is a potent inhibitor of HIV-1 protease, exhibiting an IC50 value of 0.32 nM. This compound effectively inhibits wild-type HIV-1 (HIV-1NL4-3) with an IC50 of 0.29 μM and a drug-resistant variant (HIV-1MDR) with an IC50 of 1.90 μM. Its strong antiviral activity against both strains makes HIV-1 protease-IN-8 a valuable tool for research in HIV treatment and drug resistance studies. -
HIV-1 Protease Inhibitor
HIV-1 protease-IN-5 is a potent inhibitor of HIV-1 protease, exhibiting an IC50 of 1.64 nM. This compound demonstrates significant efficacy against both wild-type and darunavir-resistant variants of HIV-1, making it a valuable tool for antiviral research. Its mechanism of action is crucial for developing therapeutic strategies to combat HIV-1 infections and resistance. -
HIV-1 Protease Inhibitor
Longipedunin A is a potent inhibitor of HIV-1 protease, exhibiting an IC50 value of 50 µg/mL. This compound effectively interferes with the proteolytic processing of viral polyproteins, thereby limiting HIV-1 replication. Longipedunin A is suitable for research applications in virology and studies focused on developing antiviral therapies. -
HIV-1 Inhibitor
U-75875 is an HIV-1 protease inhibitor that effectively impedes the processing of Gag-Pol proteins, thereby disrupting viral maturation and replication. This compound is primarily utilized in research focused on HIV-1 infection, providing valuable insights into viral life cycle mechanisms and potential therapeutic interventions. -
HIV-1 Protease Inhibitor
HIV-1 protease-IN-11 is a potent HIV-1 protease inhibitor with an IC50 value of 0.41 nM. This compound demonstrates significant efficacy against drug-resistant variants of the virus, offering opportunities for HIV research and therapeutic development. Its selective targeting of the HIV-1 protease positions it as a valuable tool in the study of HIV replication and infection mechanisms. -
HIV Proteinase Inhibitor
AG-1284 is an effective HIV proteinase inhibitor, demonstrating an EC50 of 0.5 mg/mL. This compound is utilized in research focused on HIV infection mechanisms and therapeutic strategies aimed at viral suppression. AG-1284's inhibition of HIV proteinase makes it a valuable tool for studying the virus's replication cycle and potential drug development. -
HIV Protease Inhibitor
A-77003 is a potent HIV protease inhibitor, demonstrating an IC50 range of 0.1 to 0.2 μg/ml against both HIV-1 and HIV-2 proteases. This compound exhibits significant antiretroviral activity while maintaining low cytotoxicity in vitro, making it suitable for research applications focused on HIV treatment and therapeutic development. -
HIV-1 Protease Inhibitor
A 74704 is a pseudo C2-symmetric inhibitor targeting HIV-1 protease. This compound effectively disrupts the enzymatic activity of the protease, thereby inhibiting viral replication. It serves as a valuable reagent for studying HIV pathogenesis and developing antiviral therapies. -
HIV-1 Protease Inhibitor
A-80987 is a selective inhibitor of human immunodeficiency virus type 1 (HIV-1) protease. This compound effectively disrupts the proteolytic processing of viral polyproteins, thereby hindering viral replication. A-80987 is valuable for research focused on HIV pathogenesis and therapeutic interventions targeting viral enzyme activity. -
HIV-1 Reverse Transcriptase Inhibitor
Opaviraline is a potent HIV-1 reverse transcriptase inhibitor. It effectively disrupts the viral replication process by targeting the reverse transcriptase enzyme, which is crucial for converting viral RNA into DNA. This compound is utilized in research focused on developing antiviral therapies and understanding HIV-1 resistance mechanisms. -
HIV Protease Inhibitor
Ro 31-8588 is a potent HIV protease inhibitor, exhibiting a Ki of 0.3 nM. This compound is essential for studying the role of HIV protease in viral replication and can be utilized in research focused on AIDS treatment and potential therapeutic strategies. Its high affinity makes it a valuable tool for investigating the mechanistic aspects of HIV inhibition. -
HIV-1 Protease Inhibitor
LY-289612 is a potent HIV-1 protease inhibitor, exhibiting an IC50 value of 1.5 nM. This compound effectively disrupts the proteolytic processing of viral polyproteins, thereby inhibiting the replication of HIV-1. It is utilized in research focused on developing antiviral therapies and understanding HIV resistance mechanisms. -
HIV-1 Protease Inhibitor
PL-100 is a powerful inhibitor of HIV-1 protease, exhibiting a Ki of 36 pM and an EC50 of 16 nM. This compound effectively inhibits viral replication by targeting HIV-1 protease activity, showing significant antiviral efficacy against drug-resistant strains of the virus. PL-100 is suitable for research applications focused on understanding and combating drug-resistant HIV infections. -
HIV Replication Inhibitor
PMEDAP is a potent inhibitor of human immunodeficiency virus (HIV) replication, demonstrating significant antiviral activity. In addition to its efficacy against HIV, PMEDAP exhibits anti-murine cytomegalovirus (MCMV) properties and effectively inhibits Moloney murine sarcoma virus (MSV)-induced tumor formation and associated mortality. This compound is valuable for research applications focused on viral pathogenesis and therapeutic interventions in retroviral infections. -
HIV Protease Inhibitor
2α,19α-Dihydroxy-3-oxo-urs-12-en-28-oic acid is identified as a potent inhibitor of HIV protease, exhibiting significant antiviral activity. Additionally, this compound inhibits the activation of Epstein-Barr virus early antigen (EBV-EA), demonstrating its utility in virology research. Furthermore, it displays inhibitory effects on nitric oxide production in lipopolysaccharide-activated RAW 264.7 cells, highlighting its potential applications in immunology and inflammation studies. -
HIV/EV-A71 Inhibitor
AL-470 is a potent antiviral compound targeting HIV-1, HIV-2, and EV-A71, exhibiting EC50 values of 0.27 µM, 0.63 µM, and 0.35 µM, respectively. This compound demonstrates significant inhibition of viral replication and is suitable for studies focused on HIV and enterovirus A71 infections. AL-470 serves as a valuable tool for researchers investigating antiviral mechanisms and therapeutic strategies against these viral pathogens. -
HIV/HBV Inhibitor
Emtricitabine triphosphate tetrasodium salt is the tetrasodium salt form of Emtricitabine triphosphate, a phosphorylated metabolite of Emtricitabine. This compound functions as a nucleoside reverse transcriptase inhibitor, effectively targeting both HIV and HBV. Emtricitabine triphosphate tetrasodium salt is utilized in research applications focused on antiviral drug development and the mechanisms of viral replication. -
HIV Inhibitor
(S)-Tenofovir is an S-enantiomer of Tenofovir, functioning primarily as a nucleotide reverse transcriptase inhibitor. This compound demonstrates significant biological activity against HIV and is also relevant in the treatment of chronic Hepatitis B (HBV). It is commonly utilized in research applications focused on antiviral therapies and the mechanistic study of retroviral infections. -
HIV/HBV Inhibitor
L-Fd4A is an adenine derivative that inhibits both human immunodeficiency virus (HIV) and hepatitis B virus (HBV) with effective concentrations (EC50) of 1.5 μM and 1.7 μM, respectively. This compound demonstrates promising antiviral activity while exhibiting low cytotoxicity, making it suitable for research applications in studying HIV and HBV inhibition mechanisms. -
HCV/HIV Inhibitor
C5A is a microbicidal peptide that targets and inhibits both hepatitis C virus (HCV) and human immunodeficiency virus (HIV). By disrupting the membrane integrity of the HIV virion and affecting the conical capsid core that encases the viral genome, C5A significantly reduces the infectivity of a wide range of HIV isolates in various primary target cells in vitro. Additionally, studies have demonstrated that C5A offers protective effects in mice against vaginal and rectal challenges with HIV, highlighting its potential utility in antiviral research applications. -
HIV-1 Integrase Inhibitor
GSK-1264 is an HIV-1 integrase inhibitor that targets the catalytic core and C-terminal domains of the HIV-1 integrase enzyme. By promoting the formation of an open polymer structure of integrase dimers, GSK-1264 disrupts the late stages of HIV replication and interferes with viral particle assembly. This compound is valuable for research focused on HIV infection and understanding integrase-mediated processes in the viral life cycle. -
HIV-1 Integrase Inhibitor
HIV-1 Integrase Inhibitor 8 is a selective inhibitor targeting the HIV-1 integrase enzyme. It demonstrates potent activity against viral replication by disrupting the integration of viral DNA into the host genome, which is essential for the HIV life cycle. This compound is primarily utilized in research focused on antiretroviral therapy and the development of HIV treatments, contributing to the understanding of integrase inhibition mechanisms. -
HIV-1Integrase Inhibitor
GSK3839919A is a potent allosteric inhibitor of HIV-1 integrase, targeting the enzyme responsible for the integration of viral DNA into the host genome. This compound exhibits significant antiviral activity against HIV-1, making it a valuable tool for research applications focused on the development of novel antiretroviral therapies and the study of HIV replication mechanisms. Its unique mechanism of action may provide insights into resistance pathways and inform drug design strategies. -
HIV Integrase Inhibitor
His-Cys-Lys-Phe-Trp-Trp is an HIV integrase inhibitor, exhibiting an IC50 of 2 μM. This compound impedes the integrase enzyme's function, thereby preventing viral DNA integration into the host genome. His-Cys-Lys-Phe-Trp-Trp is valuable for research focused on HIV pathogenesis and the development of antiretroviral therapies. -
HIV-1 integrase Inhibitor
(S)-BI-1001 is a potent HIV-1 integrase inhibitor, demonstrating significant antiviral activity. It exhibits an IC50 value of 28 nM, an EC50 of 450 nM, and a Kd of 4.7 μM, indicating its efficacy in disrupting viral replication processes. This compound is valuable for research applications focused on HIV-1 pathogenesis and therapeutic development. -
HIV-1 Integrase Inhibitor
HIV-1 Integrase Inhibitor 7 is a potent inhibitor of HIV-1 integrase, exhibiting an IC50 value of 33.3 nM. This compound effectively interferes with the integration of viral DNA into the host genome, making it essential for studies focused on HIV-1 replication and treatment strategies. It serves as a valuable tool in research applications aimed at understanding HIV-1 biology and developing therapeutic interventions against HIV. -
HIV-1 Integrase Inhibitor
HIV-1 Integrase Inhibitor 11 is a potent inhibitor of HIV-1 integrase, demonstrating an IC50 of 125 μM. This compound effectively disrupts the integration of viral DNA into the host genome, thereby hindering the replication process of HIV-1. It is suitable for research applications aimed at developing antiretroviral therapies and studying the mechanisms of HIV integration and resistance.
